Clinical Trial

MAGIC AKI: Magnesium for the Prevention of HIOC-Associated AKI

Study acronym: MAGIC-AKI
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
In this research study, investigators will test whether prophylactic high-dose IV Mg administration attenuates the risk of AKI in patients with malignant mesothelioma receiving intraoperative chemotherapy (HIOC) with cisplatin compared to placebo .
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2023-02-15; most recent amendment 2025-11-18.
Status change: Not Yet Recruiting → Recruiting 2023-04-03
Trial Details
NCT Number NCT05730816
Lead Sponsor Brigham and Women's Hospital
Collaborators: National Institutes of Health (NIH), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Conditions Mesothelioma
Enrollment 130 participants
Start Date 2023-04-04
Primary Completion 2027-04-03 (estimated)
Study Completion 2028-01-01 (estimated)
Updated on ClinicalTrials.gov 2025-11-21